Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321218 | PMC |
| http://dx.doi.org/10.1161/CIRCRESAHA.125.326943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Platelet Factor 4 (PF4) Regulates Hematopoietic Stem Cell Aging.
Blood
September 2025
University of Illinois at Chicago, Chicago, Illinois, United States.
Hematopoietic stem cells (HSCs) responsible for blood cell production and their bone marrow regulatory niches undergo age-related changes, impacting immune responses and predisposing individuals to hematologic malignancies. Here, we show that the age-related alterations of the megakaryocytic niche and associated downregulation of Platelet Factor 4 (PF4) are pivotal mechanisms driving HSC aging. PF4-deficient mice display several phenotypes reminiscent of accelerated HSC aging, including lymphopenia, increased myeloid output, and DNA damage, mimicking physiologically aged HSCs.
View Article and Find Full Text PDFBiomimetic nanocarriers for the therapy and management of intestinal inflammations.
Int J Pharm X
December 2025
Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida 201313, India.
Intestinal inflammation particularly inflammatory bowel disease poses significant clinical challenges due to its chronic nature, limited treatment efficacy and adverse effects of conventional therapies like corticosteroids and biologics. Biomimetic nanocarriers have emerged as a transformative strategy to overcome these limitations by leveraging natural cell membranes for targeted drug delivery. This review critically examines the application of biomimetic nanocarriers as precision therapeutics for intestinal inflammation.
View Article and Find Full Text PDFiMer, a naturally occurring MERTK splice variant, binds to GAS6 to decrease platelet activation and thrombus formation.
Blood Vessel Thromb Hemost
August 2025
Hematology, Thrombosis and Hemostasis Research Program, Versiti Blood Research Institute, Wauwatosa, WI.
Unopposed platelet activation can be associated with pathologic thrombosis. An intact growth arrest-specific gene 6 (GAS6)/Mer receptor tyrosine kinase (MERTK) signaling pathway contributes importantly to potentiating platelet activation triggered by molecular agonists ex vivo and thrombus stabilization in vivo. We describe, herein, the inhibition of platelet function and stable thrombus formation conferred by iMer, a naturally occurring MERTK splice variant, that acts as a GAS6 decoy receptor and decreases phosphorylation of MERTK.
View Article and Find Full Text PDFThe relationship between hematological parameters and coronary angiographic lesions.
Front Cardiovasc Med
August 2025
Pernambuco Cardiac Emergency Hospital, University of Pernambuco (PROCAPE, UPE), Recife, Brazil.
Atherosclerosis is the most important etiology of acute myocardial infarction, which is considered an inflammatory disease with specific cellular and molecular responses. Recent research has linked hematological variables as biomarkers of the severity of coronary artery disease. Studies suggest that nucleated red blood cells (NRBCs), neutrophil to lymphocyte ratio (NLR), and mean platelet volume (MPV) may serve as components of a laboratory model or hematological scoring system for in-hospital surveillance.
View Article and Find Full Text PDFCYP2C19 Genetic Variants Associated with Clopidogrel Resistance and Major Adverse Cardiovascular Events in Vietnamese Patients Undergoing Percutaneous Coronary Intervention.
Cardiovasc Hematol Disord Drug Targets
August 2025
Institute of Pharmacy Training, Vietnam Military Medical University, Hanoi, Vietnam.
Introduction: Acute coronary syndrome (ACS) is a leading cause of death, and clopidogrel resistance remains a major challenge in its treatment. This study aims to determine the impact of CYP2C19 genetic variants on clopidogrel resistance (CR) and major adverse cardiovascular events (MACEs) in Vietnamese patients undergoing percutaneous coronary intervention (PCI).
Methods: We carried out a descriptive cross-sectional study, supplemented by a prospective longitudinal follow-up, on 113 ACS patients undergoing PCI with drug-eluting stent implantation at the Department of Cardiology, Military Hospital 103, from January 2015 to May 2018.